Invitae Corporation
NVTA
Hisse Senetlerindeki Sıralama
#35786
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Hisse Fiyatı
$0.016
Son senkronizasyon: 2024-03-11
Piyasa Değeri
$3.27M
Değişim (1 gün)
-5.33%
Değişim (1 yıl)
5,233.33%
Ülke
US
Ticaret Invitae Corporation (NVTA)
Kategori
Healthcare
Invitae Corporation (NVTA) için kazanç
Sep 2023 itibarıyla kazanç TTM: $-1.45B
Invitae Corporation şirketinin en son finansal raporlarına göre, mevcut kazancı $-1.45B'dir. 2022 yılında şirket $-3.15B kazanç elde etti, bu 2021 yılındaki $-415.86M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Invitae Corporation için kazanç geçmişi 2016 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-1.45B | -100.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $-3.15B | 657.75% |
| 2021 | $-415.86M | -41.78% |
| 2020 | $-714.27M | 174.28% |
| 2019 | $-260.42M | 97.05% |
| 2018 | $-132.16M | 5.52% |
| 2017 | $-125.24M | 24.92% |
| 2016 | $-100.26M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $7.61B | -623.31% |
US
|
|
| $4.76B | -427.50% |
US
|
|
| $-252.70M | -82.62% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -214.03% |
US
|
